Table III.
Univariate analysis of the association between patient clinicopathological characteristics and survival in the validation dataset.
| Characteristic | OR (95% CI) | P-value |
|---|---|---|
| Age | 0.998 (0.981–1.016) | 0.860 |
| T stage | ||
| T0 | 1 (ref) | <0.001 |
| T1 | 0.139 (0.027–0.723) | 0.019 |
| T2 | 0.149 (0.036–0.617) | 0.009 |
| T3 | 0.204 (0.049–0.856) | 0.030 |
| T4 | 0.440 (0.105–1.850) | 0.263 |
| N stage | ||
| N0 | 1 (ref) | <0.001 |
| N1 | 2.378 (1.381–4.095) | 0.002 |
| N2 | 4.432 (2.364–8.311) | <0.001 |
| N3 | 4.548 (2.265–9.133) | <0.001 |
| Clinical AJCC stage | ||
| I | 1 (ref) | <0.001 |
| II | 0.643 (0.155–2.669) | 0.544 |
| III | 1.562 (0.381–6.405) | 0.536 |
| ER IMH | 0.344 (0.234–0.507) | <0.001 |
| PR IMH | 0.380 (0.252–0.571) | <0.001 |
| HER2 | 1.752 (0.432–7.107) | 0.433 |
| Nuclear grade | ||
| G1 | 1 (ref) | 0.038 |
| G2 | 7.018 (0.961–51.232) | 0.055 |
| G3 | 9.466 (1.313–68.249) | 0.026 |
| PAM50 subtype | ||
| LumA | 1 (ref) | <0.001 |
| LumB | 1.434 (0.691–2.977) | 0.333 |
| HER2-enriched | 3.280 (1.579–6.812) | 0.001 |
| Basal | 3.975 (2.356–6.706) | <0.001 |
| Normal | 0.828 (0.280–2.449) | 0.734 |
| Pathologic response | 0.257 (0.120–0.554) | 0.001 |
T, tumor; N, node; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone receptor; IMH, immunohistochemistry; LumA, luminal subtype A; LumB, luminal subtype B; Basal, basal-like subtype; Normal, normal breast-like subtype; OR, odds ratio; CI, confidence interval.